Does Rallies show 13F holders for CRBU?

Yes. Rallies tracks hedge fund and 13F ownership data for CRBU, including fund names, share counts, latest tracked quarter, and position changes when available.

Is CRBU research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CRBU. It does not provide personalized investment advice.

CRBU (Caribou Biosciences, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Caribou Biosciences, Inc. Common Stock (CRBU) is a publicly traded Healthcare sector company. As of May 21, 2026, CRBU trades at $2.01 with a market cap of $205.30M and a P/E ratio of -1.24. CRBU moved +0.76% today. Year to date, CRBU is +24.22%; over the trailing twelve months it is +81.82%. Its 52-week range spans $0.66 to $3.54. Analyst consensus is strong buy with an average price target of $9.00. Rallies surfaces CRBU's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns CRBU stock?

Hedge funds tracked by Rallies that own CRBU include Rokos Capital and Maverick Capital. The latest tracked quarter is Jun 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Caribou Biosciences, Inc. Common Stock.

CRBU Key Metrics

Key financial metrics for CRBU
Metric	Value
Price	$2.01
Market Cap	$205.30M
P/E Ratio	-1.24
EPS	$-1.59
Dividend Yield	0.00%
52-Week High	$3.54
52-Week Low	$0.66
Volume	167
Avg Volume	0
Revenue (TTM)	$11.16M
Net Income	$-148.13M
Gross Margin	0.00%

Top Hedge Funds Holding CRBU

Rokos Capital holds 840.63K shares of CRBU, changed -50.00% as of Jun 30, 2024.
Maverick Capital holds 652.54K shares of CRBU, changed +0.00% as of Mar 31, 2026.

Latest CRBU News

Caribou to Present 84-Patient Vispa-cel Durability, 48-Patient CB-011 Follow-Up at EHA — May 12, 2026
Caribou Biosciences Q4 Loss Narrows to $0.28, Revenue Surges 56% to $3.94M — Mar 5, 2026
Caribou Biosciences Shows $148.1M GAAP Loss, Secures $142.8M Cash Runway — Mar 5, 2026
Caribou Biosciences Flags Funding Needs, Forecasts Q4 Loss and $734M CB-011 Sales — Feb 24, 2026
Caribou Biosciences Outlines Pivotal Phase II/III Vispa-cel Trial, Seeks $100M — Feb 23, 2026

Recent CRBU Insider Trades

Kelly Timothy P sold 6.23K (~$12.02K) on Feb 25, 2026.
Kelly Timothy P sold 3.15K (~$6.17K) on Feb 24, 2026.
MCCLUNG BARBARA G sold 6.94K (~$13.60K) on Feb 24, 2026.

CRBU Analyst Consensus

8 analysts cover CRBU: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $9.00.

Common questions about CRBU

Who owns CRBU stock?: Hedge funds tracked by Rallies that own CRBU include Rokos Capital and Maverick Capital. The latest tracked quarter is Jun 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Caribou Biosciences, Inc. Common Stock.
Does Rallies show 13F holders for CRBU?: Yes. Rallies tracks hedge fund and 13F ownership data for CRBU, including fund names, share counts, latest tracked quarter, and position changes when available.
Is CRBU research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CRBU. It does not provide personalized investment advice.